Excellent outcome following transplantation of a domino donor liver with high-grade macrosteatosis

Pathol Res Pract. 2004;200(7-8):581-7; discussion 589-90. doi: 10.1016/j.prp.2004.06.003.

Abstract

Severe macrosteatosis in the donor liver is considered a major predictive factor of primary graft non-function. Such livers are usually discarded despite an ever-growing need for donor livers. We report our recent experience in a patient (#1) who had an excellent outcome following liver transplantation (LT) of a 65-70% macrosteatotic graft and compare his findings with those of two other (#2 and #3) recipients of moderate to severe macrosteatotic grafts. Both patients (#2 and #3) had initial diminished function, with recovery in patient #2 but delayed graft non-function requiring re-LT (day 24) in patient #3. Patient #1 had no intra-operative complications, while patient #2 had mild complications due to prior adhesions and graft capsular laceration. In patient #3, extensive intra-abdominal adhesions resulting in excessive bleeding occurred during recipient hepatectomy. Total ischemic times: 2.48, 6.10, and 8.18 h; total blood product usage: 43, 81, and 223 units; post-LT hospital stay: 9, 21, and 69 days were seen in patients #1, #2 and #3, respectively. In conclusion, post-LT excellent graft function was seen in one recipient of 65-70% macrosteatotic graft. Transplantation of grafts with moderate/severe macrosteatosis may be inadvisable in patients with extensive intra-abdominal adhesions with expectant excessive bleeding and long ischemia times.

Publication types

  • Case Reports
  • Comparative Study

MeSH terms

  • Abdomen
  • Adult
  • Contraindications
  • Fatty Liver / pathology*
  • Hepatectomy / adverse effects
  • Humans
  • Intraoperative Complications
  • Lacerations / etiology
  • Liver / injuries
  • Liver Failure / complications
  • Liver Failure / surgery*
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Reoperation
  • Severity of Illness Index
  • Tissue Adhesions / complications
  • Tissue Donors*
  • Treatment Outcome